ArticleCureus2025
From Stroke to Infection: The Emerging Role of Fibrinogen-to-Albumin Ratio in Predicting Stroke-Associated Pneumonia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStroke-associated pneumonia (SAP) is a commonly encountered complication in patients with acute ischemic stroke (AIS) and is generally manifested within the first week following stroke onset.
aimsThe objectives of this study were to determine the association of the fibrinogen-to-albumin ratio (FAR) with SAP in AIS and to examine the predictive and prognostic utility of FAR for the development of SAP.
methodsWe performed a prospective cohort study involving 44 men with AIS admitted to the stroke unit within 24 hours of onset and followed up for two weeks. Based on clinical outcomes, individual patients were classified into SAP and non-SAP groups, in addition to another 22 age-matched healthy controls. Clinical characteristics, laboratory data, and outcomes were compared for differences, and receiver operating characteristic (ROC) curves were also constructed to observe the predictive capacity of FAR.
resultsFAR uniquely distinguished the SAP group from controls with a 95.5% sensitivity and a 100% specificity at a cutoff of 0.079 (area under the curve (AUC)=0.997; p<0.001). FAR also distinguished AIS-only patients from controls with an 81.8% sensitivity and a 95.5% specificity at a cutoff of 0.072 (AUC=0.946; p<0.001).
conclusionFAR is a simple, robust biomarker and may independently predict the risk of SAP in AIS patients. Its very high discriminative accuracy for distinguishing SAP from both non-SAP stroke and healthy controls supports its rationale in early risk stratification and prediction. Usage of FAR in clinical assessment could facilitate the early detection of such patients, allow scope for therapeutic intervention based on individual risk, and reduce SAP-related morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.